Dania Therapeutics

Alixia Therapeutics

The company develops therapeutic compounds that disrupt metabolic and inflammatory pathways in the tumor ecosystem for patients with drug-resistant cancer.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

Tanai Therapeutics

This company develops oral small molecule therapeutics targeting energy expenditure pathways to treat obesity and cardiometabolic diseases for patients.

Calithera

This pharmaceutical company develops small-molecule drugs targeting cancer metabolism and tumour immunology for healthcare providers and patients with oncology and haematology conditions.

Scorpion Therapeutics

This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Chromacure

This company develops small molecule therapeutics for oncology patients to address unmet clinical needs in cancer treatment.

Roca Therapeutics

The company develops small molecule therapies for patients with severe ocular diseases and cancers such as uveal melanoma.